Evidence map›Paper›PMID 40976979›Full record

ArticlePhysiological reports2025

Dietary influences on chemotherapy sensitivity and cardiotoxicity modulated by IRE1 targeting in triple-negative breast cancer in female mice.

Yismeilin R Feliz-Mosquea, Adam S Wilson, Nildris Cruz-Diaz, Valerie S Payne, Katherine L Cook, David R Soto-Pantoja

Abstract read
In one paragraph

Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yismeilin R Feliz-MosqueaDepartment of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Adam S WilsonDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Nildris Cruz-DiazDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Valerie S PayneDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Katherine L CookDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
David R Soto-PantojaDepartment of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0003-0107-7678

Funding

American Cancer Society (ACS) RSG-19-150-01-LIBNational Institutes of Health-National Cancer Institute P30CA012197National Institutes of Health-National Institute of General Medical Sciences 5T32GM127261-04Susan G. Komen (SGK) CCR18547795
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) predominantly affects young and minority women, with cytotoxic chemotherapy regimens causing severe side effects, including chronic cardiac dysfunction. Obesity worsens TNBC survival. Inositol-requiring enzyme-1 (IRE1), a key arm of the unfolded protein response (UPR), influences tumor progression. Using a TNBC mouse model with control and Western diets, we tested IRE1-targeting antisense morpholino and doxorubicin. Targeting IRE1 alone reduced tumor growth and, combined with doxorubicin, did not interfere with the oncologic efficacy of this drug. We observed that increased activation of caspase-3 was consistently activated by IRE1 in tumors regardless of diet and combination treatment. Furthermore, the blockade of IRE1 mitigated chemotherapy-induced cardiotoxicity by preserving systolic dysfunction, reducing cardiac fibrosis, and preventing cell death. The potential difference in cell death mechanisms observed between the heart and tumors may be associated with different levels of oxidative stress as measured by 4HNE in our in vivo model. Thus, systemic IRE1 suppression protected cardiac tissue while preserving the oncologic efficacy of anthracyclines.

Indexed as

Antineoplastic AgentsCardiotoxicityDoxorubicinEndoribonucleasesProtein Serine-Threonine KinasesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleMiceAntineoplastic AgentsDoxorubicinEndoribonucleasesErn1 protein, mouseProtein Serine-Threonine Kinasescardiac damagedoxorubicininositol‐requiring enzyme 1 (IRE1)lung metastasestriple‐negative breast cancer

Identifiers

PMID40976979
PMCPMC12451018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.